Related Experiment Video
Updated: Feb 17, 2026
08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
10.4K
Cardiotoxicity associated with bortezomib: A single-center experience
Murali Krishna Gurram1, Swaroopa Pulivarthi2, Kirsten Ehresmann3
1Department of Internal Medicine, HealthEast Care System, St. Paul, Minnesota, 55102, USA.
Journal of Cancer Research and Therapeutics
|December 15, 2017
Summary
Cardiotoxicity is uncommon in patients receiving bortezomib, with only 14% experiencing events, often linked to pre-existing cardiac conditions. This study suggests bortezomib is unlikely to be the cause of cardiotoxicity.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Background:
- Limited data exists on cardiotoxicity prevalence with bortezomib treatment.
- Bortezomib is used for multiple myeloma and other malignancies.
Purpose of the Study:
- To determine the prevalence of cardiotoxicity in patients treated with bortezomib.
- To investigate the relationship between bortezomib and cardiotoxicity in cancer patients.
Main Methods:
- Retrospective chart review of 64 patients treated with bortezomib.
- Evaluation of oncologic conditions and cardiac events during treatment.
Main Results:
- 14% (9/64) of patients developed cardiotoxicity.
- Most cardiotoxicity cases had prior cardiac history or risk factors.
- No significant causal link found between bortezomib and cardiac events.
Conclusions:
- Cardiotoxicity appears unrelated to bortezomib, despite some case reports.
- Further multicenter, prospective studies are needed to confirm these findings.
Related Concept Videos
01:24Drug Toxicity: Risk factors
18
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
18
01:29Cardiomyopathy V: Interprofessional Care
483
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
483
01:30Cardiomyopathy II: Dilated Cardiomyopathy
594
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
594
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
282
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
282
01:16Drug toxicity: Idiosyncratic Reactions
21
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
21
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
539
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
539